NCT06790901

Brief Summary

We know that respiratory functions of patients are affected under general anaesthesia. Although there are many underlying causes of ventilation-perfusion mismatch in the airways, the main cause is atelectasis during general anaesthesia. Atelectasis occurs in almost all patients receiving general anaesthesia. The main cause of atelectasis is the loss of muscle tone during general anaesthesia. Postoperative atelectasis was described in the last century. It is defined as the closure of the alveoli due to a decrease in inspiratory force and collapse of the lung and the resulting loss of aeration. Inhalation anaesthetics have been shown to cause hypoxic pulmonary vasoconstriction in studies. However, not all inhalation anaesthetics affect the airways in the same way. In patients who will undergo surgical procedures under different general anaesthesia maintenance methods, conditions that disrupt the ventilation-perfusion balance in the lung peroperatively can be diagnosed and monitored early, easily and inexpensively by lung ultrasonography. Lung ultrasound is a noninvasive, reliable, reliable, radiation-free imaging method that provides instantaneous imaging at the bedside. Lung ultrasound score is a scoring system that provides scoring of the loss of ventilation in the lung. For this purpose, it was aimed to divide both lung tissues into 12 areas and to give a score between 0 and 3 points and to show the severity of the loss of aeration according to the resulting total score.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 15, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 12, 2025

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

January 13, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 24, 2025

Completed
Last Updated

January 24, 2025

Status Verified

January 1, 2025

Enrollment Period

12 months

First QC Date

January 13, 2025

Last Update Submit

January 19, 2025

Conditions

Keywords

Lung Ultrasound Scoregeneral anesthesiaAtelectasisInhalation agents

Outcome Measures

Primary Outcomes (1)

  • Peroperative Atelectasis

    from induction to postoperative 1st hour

Study Arms (3)

Group Total IV anesthesia

Procedure: LUNG ULTRASOUND

Group Sevoflurane

Procedure: LUNG ULTRASOUND

Group Desflurane

Procedure: LUNG ULTRASOUND

Interventions

Determination of atelectsis By Lung Ultrasound Score

Group DesfluraneGroup SevofluraneGroup Total IV anesthesia

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

18-65 years old, ASA I-II, who will undergo rhinoplasty, septorhinoplasty operation

You may qualify if:

  • years old ASA I-II Surgical procedure time between 2 hours and 5 hours in supine position Patients who will undergo rhinoplasty, septorhinoplasty operation Patients whose consent was obtained with an informed consent form

You may not qualify if:

  • Those with a history of malignant hyperthermia,
  • People with alcohol or drug addiction,
  • Presence of dementia or confusion,
  • Uncooperative patients,
  • Those with respiratory disease,
  • Those with coronary artery disease, congestive heart failure,
  • Patients with unstable blood pressure,
  • Significant anaemia, liver or kidney disease,
  • Women during pregnancy or lactation,
  • Allergy to anaesthetic agents,
  • Body mass index (BMI) \>30 kg/m2,
  • Those with sepsis or bacterial infection, Body temperature below 35°C and above 38°C at control value

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zonguladk Bulent ecevit University

Zonguldak, Kozlu, 67600, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pulmonary Atelectasis

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 13, 2025

First Posted

January 24, 2025

Study Start

September 15, 2023

Primary Completion

August 30, 2024

Study Completion

January 12, 2025

Last Updated

January 24, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations